A randomized, double-blind study of a combination of amlodipine and irbesartan in patients with essential hypertension who insufficiently responded to amlodipine once daily
Latest Information Update: 10 May 2018
At a glance
- Drugs Amlodipine/irbesartan (Primary)
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Dainippon Sumitomo Pharma
- 22 Feb 2012 New source identified and integrated: Japic Clinical Trials Information
- 21 Feb 2012 New trial record
- 01 Feb 2012 Results from this trial were used in an NDA that was submitted to regulatory authorities in Japan